WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
about
WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
WM130 preferentially inhibits ...... β/β-catenin signaling pathway.
@en
WM130 preferentially inhibits ...... β/β-catenin signaling pathway.
@nl
type
label
WM130 preferentially inhibits ...... β/β-catenin signaling pathway.
@en
WM130 preferentially inhibits ...... β/β-catenin signaling pathway.
@nl
prefLabel
WM130 preferentially inhibits ...... β/β-catenin signaling pathway.
@en
WM130 preferentially inhibits ...... β/β-catenin signaling pathway.
@nl
P2093
P2860
P356
P1433
P1476
WM130 preferentially inhibits ...... β/β-catenin signaling pathway.
@en
P2093
Chen-Xu Ni
Hong-Gang Hu
Jun-Ping Zhang
Wei-Heng Xu
P2860
P304
79544-79556
P356
10.18632/ONCOTARGET.12822
P407
P577
2016-10-22T00:00:00Z